Contents

ORIGINAL ARTICLE

Basic Study
1216 Pathological significance of abnormal receptor d’origine nantais and programmed death ligand 1 expression in colorectal cancer
Liu YZ, Han DT, Shi DR, Hong B, Qian Y, Wu ZG, Yao SH, Tang TM, Wang MH, Xu XM, Yao HP

1237 Decreased expression of the long non-coding RNA HOXD-AS2 promotes gastric cancer progression by targeting HOXD8 and activating PI3K/Akt signaling pathway

1255 Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma
Sheng QJ, Tian WT, Dou XG, Zhang C, Li YW, Han C, Fan YX, Lai PP, Ding Y

Case Control Study
1272 LncRNA C9orf139 can regulate the growth of pancreatic cancer by mediating the miR-663a/Sox12 axis
Ge JN, Yan D, Ge CL, Wei MJ

Retrospective Cohort Study
1288 Cancer-related microangiopathic hemolytic anemia in patients with advanced gastric cancer: A retrospective single-center analysis
Berger AK, Allgäuer M, Apostolidis L, Schulze-Schleithoff AE, Merle U, Jaeger D, Haag GM

1296 Influence of primary tumor location and resection on survival in metastatic colorectal cancer
Tharin Z, Blanc J, Charifi Alaoui I, Bertaut A, Ghiringhelli F

Retrospective Study
1311 Highly accurate colorectal cancer prediction model based on Raman spectroscopy using patient serum

1325 Subtotal gastrectomy combined with chemotherapy: An effective therapy for patients with circumscribed Borrmann type IV gastric cancer
Huang HB, Gao ZM, Sun AQ, Liang WT, Li K

Randomized Controlled Trial
1336 Diagnostic value of novel retroflexion colonoscopy in the right colon: A randomized controlled trial
META-ANALYSIS

1346  Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
Yang L, Dong XZ, Xing XX, Cui XH, Li L, Zhang L.

CASE REPORT

1364  Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report

1372  Cutaneous metastases of pancreatic carcinoma to the labia majora: A case report and review of literature
Shi Y, Li SS, Liu DY, Yu Y
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Tomohide Hori, PhD, MD, FACS, is an Attending Surgeon at the Affiliated Hospital with Kyoto University (Kyoto, Japan). Dr. Hori obtained his medical doctor license from Tokyo Medical University (Japan) in 1997 and his Doctor of Philosophy degree from Mie University Graduate School of Medicine (Japan) in 2007. Dr. Hori is certified and qualified by many international and domestic societies, including the American College of Surgeons and Japan Society of Endoscopic Surgery. From 2009 to 2011, he worked at Mayo Clinic (Jacksonville, FL, United States). Dr. Hori’s research career has spanned the fields of gastroenterology, hepatology, transplant immunology, and gastrointestinal, colorectal, hepatobiliary, pancreatic, transplant and pediatric surgeries, yielding more than 200 medical publications in international journals. Currently, Dr. Hori serves as editorial board member of Annals of Gastroenterology (the official journal of Hellenic Society of Gastroenterology, Athens, Greece). (L-Editor: Filippodia)

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, and PubMed Central. The 2020 edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJGO as 2.898; IF without journal self cites: 2.880; 5-year IF: 3.316; Ranking: 143 among 244 journals in oncology; Quartile category: Q3; Ranking: 55 among 88 journals in gastroenterology and hepatology; and Quartile category: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Jia-Hui Li; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Rosa M Jimenez Rodriguez, Pashtoon Kasi, Monjur Ahmed

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
November 15, 2020

COPYRIGHT
© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2020 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Retrospective Cohort Study

Cancer-related microangiopathic hemolytic anemia in patients with advanced gastric cancer: A retrospective single-center analysis

Anne Katrin Berger, Michael Allgäuer, Leonidas Apostolidis, Anna Elisa Schulze-Schleithoff, Uta Merle, Dirk Jaeger, Georg Martin Haag

ORCID number: Anne Katrin Berger 0000-0002-0906-4401; Michael Allgäuer 0000-0003-4518-7887; Leonidas Apostolidis 0000-0002-6358-8206; Anna Elisa Schulze-Schleithoff 0000-0003-1914-0866; Uta Merle 0000-0003-1386-3350; Dirk Jaeger 0000-0002-1276-7802; Georg Martin Haag 0000-0002-9410-9968.

Author contributions: Berger AK completed conception and design, acquisition of data, analysis and interpretation of data, writing and revision of the manuscript; Allgäuer M and Apostolidis L finished analysis and interpretation of data, rewriting and review of the manuscript, technical support; Schulze-Schleithoff AE, Merle U and Jaeger D completed acquisition of data, writing and review of the manuscript; Haag GM finished conception and design, acquisition of data, analysis and interpretation of data, writing and review of the manuscript; All authors approved the final manuscript version.

Institutional review board statement: The study was approved by the local Ethics Committee University of Heidelberg, No. S-335/2014.

Informed consent statement: According to local ethics policy for retrospective analysis of own

Abstract

BACKGROUND
Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia and organ failure caused by tumor-associated thrombotic microangiopathy (TMA) is a life-threatening oncological emergency. Rapid diagnosis and precise distinction from other forms of TMA is crucial for appropriate therapy, which aims at treating the underlying malignancy. However, the prognosis of patients with cancer-related (CR)-MAHA is limited. To date, less than 50 patients with gastric cancer and CR-MAHA have been reported, mainly as single case reports, and detailed information on treatment strategies and outcome are scarce. We analyzed the characteristics and outcomes data of CR-MAHA patients with gastric cancer treated at our center between 2012 and 2019.

AIM
To gain knowledge about CR-MAHA and the course of disease.

METHODS
We retrospectively analyzed patients using an institutional prospectively maintained database. Patients who had CR-MAHA but other cancer types or cancer of unknown primary were excluded. The basic requirements for inclusion
were: Histologically proven gastric adenocarcinoma; and clinical diagnosis of hemolytic anemia with schistocytes with or without thrombocytopenia. The observation period for each patient started with the first day of documented symptoms. The follow-up period for this analysis ended on February 1, 2020.

RESULTS
We identified eight patients with a median age of 54 years. Histologically, all patients had (partial) diffuse subtypes of gastric adenocarcinoma with partial or complete signet cell morphology. All patients had metastatic disease and one patient had a microsatellite instability-high (MSI-H) tumor. In three patients, clinical signs of MAHA preceded the diagnosis of cancer, and in two patients, CR-MAHA indicated recurrent disease. All patients had severe hemolytic anemia and thrombocytopenia. Six patients experienced severe bone pain, and five patients had dyspnea. Systemic, 5-fluorouracil-based combination chemotherapy was initiated in six patients, which resulted in rapid initial response with significant improvement of clinical symptoms and blood values. Progression-free survival (PFS) of the whole cohort was 1.9 wk and median overall survival (OS) was 1.9 wk. For patients with chemotherapy, PFS was 9.0 wk and OS was 10.3 wk. The patient with the MSI-H tumor has been undergoing immunotherapy for more than 3 years.

CONCLUSION
The benefit of chemotherapy in CR-MAHA patients is limited. Immunotherapy for patients with MSI-H tumors may lead to long-term tumor control even in CR-MAHA patients.

Key Words: Microangiopathic hemolytic anemia; Gastric cancer; Chemotherapy; Second-line chemotherapy; Thrombocytopenia; Microsatellite instability-high tumor

INTRODUCTION
Tumor-associated thrombotic microangiopathy (TMA) caused by systemic microvascular metastases and bone marrow involvement is a life-threatening oncological emergency leading to microangiopathic hemolytic anemia (MAHA) with thrombocytopenia and organ failure of variable severity[1]. This alarming and often fatal clinical constellation is described as a rare event in several solid tumors entities and may sometimes reveal occult disseminated malignancy[2,3]. It has to be clearly distinguished from drug-induced TMA in cancer patients[4] and hereditary or acquired
primary TMA syndromes such as ADAMTS13 deficiency or Shiga toxin-mediated TMA\(^\text{5}\). Those forms are also clinically characterized by MAHA, thrombocytopenia and organ injury, but based on diverging underlying pathomechanisms, immediate specific therapeutic measures like plasma exchange treatment or application of eculizumab\(^\text{6,7}\) can be crucial for forms of primary TMA. For cancer patients with drug-induced TMA, removal of the causative drug is often sufficient\(^\text{1}\). In contrast, for patients with cancer-related (CR)-MAHA, the only beneficial therapy is the treatment of the underlying malignancy, highlighting the need for rapid diagnosis to avoid ineffective therapeutic interventions such as plasmapheresis. Still, the prognosis of this subgroup of cancer patients is very poor\(^\text{8}\).

To date, the most comprehensive clinical data for CR-MAHA patients come from two heterogeneous thrombotic thrombocytopenic purpura (TTP)-registry series that included 10 and 20 patients with different tumor types\(^\text{2,9}\). Gastric cancer was identified in 13.3% (4/30) of those patients. A large retrospective literature review covering a time period of 33 years reported on 168 CR-MAHA patients and identified another 40 patients with gastric cancer, reported mainly as single case reports\(^\text{8}\). Here, we add our experience with 8 patients presenting with CR-MAHA and gastric cancer treated at our university hospital center between 2012 and 2019. We present the patients’ clinical and laboratory findings and outcomes, and report our experience with oncological treatment for this rare condition. To the best of our knowledge, this is the largest cohort of gastric cancer patients with CR-MAHA reported to date.

### MATERIALS AND METHODS

#### Patients

We identified patients who were diagnosed with CR-MAHA and gastric adenocarcinoma at our center between January 2012 and January 2020. Patients who had CR-MAHA but other cancer types or cancer of unknown primary were excluded from this analysis. The data were obtained from an institutional prospectively maintained database. The basic requirements for inclusion were histologically proven diagnosis of gastric adenocarcinoma; and clinical diagnosis of hemolytic anemia with schistocytes with or without thrombocytopenia. The observation period for each patient started with the first day of documented symptoms. The follow-up period for this analysis ended on February 1, 2020.

#### Assessment

If systemic treatment was initiated, the choice of treatment was up to the attending oncologist considering the individual patient’s condition. When antitumor treatment was withheld, this was a shared decision considering the patient’s choice, his condition, and the physician’s advice. Clinical data were routinely collected and documented by the attending oncologists and medical staff via an electronic medical record. Information included: Time of first CR-MAHA-associated symptoms, time of diagnosis of MAHA from or to diagnosis of gastric cancer (prior, concurrent, after), site and histologic subtype of carcinoma, laboratory features, clinical signs of organ failure, histologic analysis of the bone marrow, start and stop date of antitumor treatment, response to therapy, and date of progression and date of death.

Overall survival (OS) was defined as the time from documented CR-MAHA diagnosis to death. Progression-free survival (PFS) was defined as the time from CR-MAHA diagnosis to documented tumor progression or death, whichever occurred first. Residual survival (RS) among patients with salvage therapy was defined as the time from start of second-line therapy to death. Diagnosis of CR-MAHA was defined as the timepoint when the term was documented the first time. Onset of CR-MAHA symptoms was defined as the first documented medical contact (as inpatient or outpatient) the patient had for associated symptoms (e.g., dyspnea, pain, bleeding) or laboratory findings (anemia, thrombocytopenia, coagulopathy).

#### Ethics approval

The study was approved by the local Ethics Committee University of Heidelberg, No. S-335/2014.
RESULTS

Patients demographics

We identified 8 patients meeting the inclusion criteria. An overview of the patients’ characteristics is given in Table 1. The median age was 50 years (range 28-76) for diagnosis of gastric cancer and 54 years (range 28-76) for diagnosis of CR-MAHA. Four patients were female. The gastric carcinoma was located in the stomach in 7 patients (87.5%), and at the gastroesophageal junction in 1 patient (12.5%). Histologically, 4 patients (50%) had adenocarcinomas of the diffuse subtype, and 4 patients (50%) showed mixed intestinal/diffuse differentiation. In all cases, the tumor was of partial or complete signet ring cell morphology. Five patients (62.5%) were human epidermal growth factor receptor 2 (HER2)-negative, and HER2 status was unknown in 3 patients (37.5%). One patient (12.5%) had microsatellite instability-high (MSI-H) tumor, and MSI status is unknown in all other patients. All patients had metastatic disease. Five patients (62.5%) had synchronous metastases, and 3 patients (37.5%) had secondary metastatic disease after definitive surgery that occurred 0.5, 2, and 10 years, respectively, after first treatment. For all patients, survival data were available. At time of database lock, 7 patients (87.5%) had died of their disease.

CR-MAHA

In 3 patients (37.5%), clinical signs of MAHA preceded the diagnosis of cancer. Before admission to our hospital, these patients were inpatients or outpatients of external medical facilities. One patient was admitted to our hospital with severe backpain, anemia and thrombocytopenia, suspected to have “acute leukemia” only days after the patient sought medical attention for the first time. The second patient was transferred after 5 days with “unclear coagulopathy.” The third patient had been under diagnostic evaluations for backpain and progressing anemia and thrombocytopenia for 3 wk. In 2 patients (25%), CR-MAHA indicated recurrent disease after 0.5 and 10 years, respectively. The patient with recurrent metastatic disease after 10 years was treated at an external hospital for severe backpain and thrombocytopenia for 6 d, and the patient with secondary metastases after 0.5 years presented in our emergency department with new back pain, fever and dyspnea. In 2 patients (25%), onset of CR-MAHA was concurrent with first cancer diagnosis, and 1 patient (12.5%) was under palliative chemotherapy (paclitaxel-ramucirumab) when CR-MAHA occurred.

In all patients, laboratory analysis revealed hemolytic anemia with a median hemoglobin concentration of 7.7 g/dL (range 5.4-8.4 g/dL, reference 12-16 g/dL), median schistocytes of 33% (range 15-97%, reference < 5%) and decreased haptoglobin (< 0.1 g/L, reference 0.3-2.0 g/L). The median platelet count was 40/nL (range 8-168/nL, reference 150-440/nL). Median lactate dehydrogenase level was 853 U/L (range 415-4765 U/L, reference < 249 U/L). At time of CR-MAHA, 1 patient (12.5%) had intermittent neurological symptoms (aphasia), 6 (75%) suffered from dyspnea and 5 (62.5%) complained about severe backpain, requiring analgesia with opioids. In 5 of 8 patients (62.5%), bone marrow biopsy was performed, of which 3 showed infiltration by adenocarcinoma (Figure 1). In 1 patient there were no signs of infiltration and 1 patient had a dry tap.

Antitumor treatment

After diagnosis of CR-MAHA, systemic chemotherapy was administered in 6 patients (75%). Median time between CR-MAHA diagnosis at our center and start of chemotherapy was 1 d (range 0-2). Median time between first symptoms and start of chemotherapy was 5 d (range 0-22). All patients received 5-fluorouracil (5-FU)-based combinations. Three (37.5%) patients were treated with a triple combination according to the FLOT regimen10, 3 patients (37.5%) received doublet combinations (5-FU plus oxaliplatin in 2 cases, 5-FU plus irinotecan and ramucirumab in 1 case). Four patients (66.7% of patients starting treatment) showed rapid initial response to chemotherapy with significant improvement of clinical symptoms and blood values already before the second cycle at day 14 (Table 2). Two patients (25%) deteriorated rapidly despite chemotherapy and died only 1 and 5 d afterwards. Three patients (37.5%) received second-line chemotherapies (FOLFIRI, FOLFIRI-ramucirumab and paclitaxel, respectively). In one patient (patient 4), further analysis revealed a MSI-H tumor. Thus, after showing disease progression during treatment with FOLFIRI/ramucirumab, a checkpoint inhibitor therapy was initiated. A detailed summary of patients and treatment responses is given in Table 2.
## Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age</th>
<th>Site of tumor</th>
<th>CR-MAHA</th>
<th>Metastases</th>
<th>Initial symptoms</th>
<th>Onset symptoms to diagnosis in d</th>
<th>Chemotherapy for CR-MAHA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>47</td>
<td>Stomach</td>
<td>Prior</td>
<td>OSS, LN, OVA</td>
<td>BP</td>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>68</td>
<td>Stomach</td>
<td>After</td>
<td>LR, PUL</td>
<td>DYS, BP</td>
<td>4</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>53</td>
<td>Stomach</td>
<td>Prior</td>
<td>OSS, LN</td>
<td>DYS, BP</td>
<td>22</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>36</td>
<td>GE-junction</td>
<td>After</td>
<td>OSS, HEP</td>
<td>DYS, BP</td>
<td>0</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>61</td>
<td>Stomach</td>
<td>Concurrent</td>
<td>OSS, PC, PUL, LN</td>
<td>DYS</td>
<td>0</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>54</td>
<td>Stomach</td>
<td>After</td>
<td>OSS, PUL</td>
<td>DYS, BP</td>
<td>6</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>28</td>
<td>Stomach</td>
<td>Concurrent</td>
<td>HEP</td>
<td>DYS, APH</td>
<td>10</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>76</td>
<td>Stomach</td>
<td>Prior</td>
<td>OSS, PUL</td>
<td>No</td>
<td>5</td>
<td>No</td>
</tr>
</tbody>
</table>

1 age at microangiopathic hemolytic anemia diagnosis.
2 time of diagnosis of microangiopathic hemolytic anemia from or to diagnosis of gastric cancer. APH: Aphasia; BP: Back pain; CR-MAHA: Cancer-related microangiopathic hemolytic anemia; DYS: Dyspnea; F: Female; GE: Gastroesophageal; HEP: Hepatic (liver); LN: Lymph node; LR: Local recurrence; M: Male; OSS: Osseous (bone); OVA: Ovary; PUL: Pulmonary; PC: Peritoneal carcinoma.

## Table 2 Treatment and response

<table>
<thead>
<tr>
<th>Patient number</th>
<th>1st chemo therapy</th>
<th>2nd chemo therapy</th>
<th>MAHA baseline</th>
<th>MAHA day 14</th>
<th>PFS in wk</th>
<th>RS in wk</th>
<th>OS in wk</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>FLO</td>
<td>FOLFIRI</td>
<td>8 5.9 31 84 9.6 12</td>
<td>9 1.1 10.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td>NA</td>
<td>32 7.7 40 NA NA NA 0.1</td>
<td>NA 0.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>FLO</td>
<td>Paclitaxel</td>
<td>34 8.0 15 65 10.7 NA</td>
<td>25.7 0.1 27.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>FOLFIRI-Ram¹</td>
<td>NA</td>
<td>168 5.4 40 204 11.6 NA</td>
<td>32.1 NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>FLOT</td>
<td>No</td>
<td>130 7.8 35 NA NA 1.0</td>
<td>NA 1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>FLOT</td>
<td>FOLFIRI-Ram</td>
<td>44 8.4 25 208 8.8 25</td>
<td>25.4 2.3 28.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>FLOT</td>
<td>No</td>
<td>46 6.9 97 NA NA 0.3</td>
<td>NA 0.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>No</td>
<td>NA</td>
<td>36 8.2 17 NA NA 1.86</td>
<td>NA 1.86</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹Diagnosis of microsatellite instability-high tumor. FLO: 5-Fluorouracil (5-FU), leucovorin, oxaliplatin; FLOT: 5-FU, leucovorin, oxaliplatin, docetaxel; FOLFIRI: 5-FU, leucovorin, irinotecan; Hb: Hemoglobin (gram per deciliter); NA: Not applicable; OS: Overall survival; PFS: Progression-free survival; Plt: Platelet count (per nanoliter); RAM: Ramucirumab; RS: Residual survival; Sch: Schistocytes (per milliliter).

### Progression and survival

At time of analysis, 7 patients had died of their disease. The median PFS of the whole cohort was 1.9 wk (95% confidence interval [CI]: 0.0-12.9), median OS was 1.9 wk (95%CI: 0.0-14.7). For the 6 patients starting chemotherapy, PFS was 9.0 wk (95%CI: 0.0-38.3) and OS was 10.3 wk (95%CI: 0.0-41.7). For patients who received second-line chemotherapy after progression, median RS was 1.1 wk (95%CI: 0.0-3.2). The patient with the MSI-H tumor has been undergoing immunotherapy for more than 3 years.

### DISCUSSION

CR-MAHA was first described in 1970 by Brain et al[11] in 12 patients with metastatic mucin-secreting adenocarcinomas of which 6 were of gastric origin. Less than 50 patients with gastric cancer and CR-MAHA have been described, mainly as single case reports[11]. The pathogenesis of CR-MAHA is not completely understood. Microvascular obstruction with tumor emboli causing red cell fragmentation and
platelet consumption especially in the bone marrow and the lung are supposed to be the underlying pathological mechanism\(^1\), which is in part supported by available autopsy data\(^3\). Of note, all of our patients showed, at least partial, signet ring cell morphology of their tumors. Brain et al\(^1\) presumed that mucin-forming tumor cells may especially promote CR-MAHA. The incidence of CR-MAHA is estimated to be 0.25-0.45 persons per million per year\(^8\) but data on CR-MAHA in overall cancer cases or for different cancer entities are lacking. At our center, between 2012 and 2020, approximately 4% of patients newly diagnosed with metastatic gastric cancer receiving palliative treatment developed CR-MAHA. This rather high rate might be explained by the fact that the awareness of our specialized oncologic center for CR-MAHA is high and that predominantly patients with high tumor burden and/or critical clinical symptoms are sent to our center.

Clinically, a rapid and precise distinction between CR-MAHA and other MAHA forms is crucial, since misdiagnosis, e.g., as a primary TMA syndrome will result in inadequate and resource-consuming treatments, including therapeutic plasma exchange\(^13\). Given the observed often dramatic clinical deterioration of patients within days and the dismal survival times of 3 d reported by others\(^2\), it is evident that a prolonged diagnostic process can close the narrow time-window for application of systemic antitumor treatment. We had the experience that cross-specialty awareness for CR-MAHA leads to marked improvements in timely diagnosis of this condition. Helpful distinguishing clinical features of patients with CR-MAHA were published by Morton et al\(^1\). In line with these, dyspnea as well as the occurrence of severe back or bone pain, exceeding the extent of radiologically apparent metastatic disease, were recurrent clinical findings in our cohort. One of our patients developed CR-MAHA while under palliative chemotherapy with paclitaxel and ramucirumab. Drug-induced MAHA was considered unlikely using the Morton criteria, and a later bone marrow biopsy revealed metastatic infiltration by signet ring cells. Distinguishing CR-MAHA from CR-disseminated intravascular coagulation (DIC) can be challenging. However, the vast majority (87.5%) of our patients had no signs of consumption coagulopathy or fibrinolysis when MAHA was diagnosed. In patients with a prolonged clinical history of MAHA-suspect symptoms, coagulation parameters might be altered since CR-MAHA itself can cause a secondary DIC due to organ damage. In addition, more severe microangiopathic changes on the blood smear can be observed in patients with CR-MAHA in comparison to DIC patients. In our patient with slight laboratory signs of coagulopathy, prolonged CR-MAHA was considered as the more appropriate clinical diagnosis in line with his significantly increased schistocytes and the severely decreased hemoglobin levels.

Our data show, that with prompt application of systemic chemotherapy a subset of patients can achieve tumor control and a relieve of symptoms for a limited time period (mostly few months). The small patient number does not allow for comparison of different chemotherapeutic regimen in this setting. Whether primary immunotherapy in MSI-H CR-MAHA patients would be more beneficial remains unclear, but the required prompt clinical response rather demands for combined chemotherapy to rapidly reduce tumor burden. However, the OS of CR-MAHA patients is clearly reduced compared to unaffected patients with metastatic gastric carcinoma where the median survival is currently in the range of 10-12 mo\(^14\). Of interest, among all of our patients undergoing second-line therapy, disease progression during first-line

---

**Figure 1** Histopathology of diffuse type gastric adenocarcinoma, patient 2. A: Discohesive tumor cells with a prominent intracytoplasmic mucin vacuole and peripherally displaced and compressed nucleus (signet ring cell morphology) diffusely infiltrate muscular layers of the gastric wall; B and C: Bone marrow core needle biopsy from the right iliac crest with residual hematopoietic elements and diffuse carcinomatous infiltrates composed of pale signet ring cells. Immunohistochemical staining for epithelial cell adhesion molecule is positive confirming the epithelial nature of cell infiltrates. A-C: Original magnification, 400 ×. A and B, hematoxylin and eosin staining.
treatment manifested with recurrent onset of bone pain and deterioration of blood test results. Thus, laboratory analysis should be performed diligently and could probably be used for early identification of insufficient tumor control. However, the RS after start of second-line treatment was dismal with only a few days. Therefore, the use of chemotherapy beyond the first-line situation seems questionable and should be discussed individually with the patient on a case-by-case basis.

To the best of our knowledge, this is the first report of a patient with CR-MAHA and a MSI-H tumor. Of note, this patient achieved long-term tumor control with the best long-term survival of all CR-MAHA patients reported to date. Thus, in patients with CR-MAHA and successful initial disease stabilization, further testing for MSI seems reasonable and may offer the chance for long-term survival.

CONCLUSION

CR-MAHA is a rare event in patients with gastric cancer that can occur at every time point during the course of disease. Rapid diagnosis of CR-MAHA may allow for application of systemic chemotherapy, which is the only causative treatment. Chemotherapy can lead to a disease stabilization and relief of symptoms for a limited time period. The results of second-line approaches are disappointing. CR-MAHA patients with MSI-H tumors may benefit enormously from checkpoint inhibition including long-time tumor control. Thus, MSI testing is strongly recommended.

ARTICLE HIGHLIGHTS

Research background
Cancer-related microangiopathic hemolytic anemia (CR-MAHA) is an infrequent but alarming oncological emergency in patients with solid tumors. Advanced gastric cancer seems among the tumor types with the highest association with CR-MAHA. Data on appropriate treatment and patients’ outcome are scarce.

Research motivation
To obtain knowledge about CR-MAHA and the course of disease to help guide treatment decisions in future patients with CR-MAHA and gastric cancer.

Research objectives
Frequency, patient and tumor characteristics, symptom load, treatment efficacy and patient outcomes.

Research methods
We analyzed a prospectively maintained database for patients with CR-MAHA and gastric cancer at our high-volume university cancer center between 2012 and 2019.

Research results
We identified 8 patients of whom 6 started polychemotherapy. Four of six showed initial response to treatment, but the survival was poor. Patients under chemotherapy had an overall survival (OS) of 10.3 wk. For the whole cohort, OS was 1.9 wk. One patient with microsatellite instability-high (MSI-H) tumor responded extremely well to immunotherapy with long-time survival exceeding 3 years.

Research conclusions
CR-MAHA in gastric cancer patients is a condition with an overall limited prognosis. Some patients respond to first-line treatment for several months. Second-line treatment does not seem beneficial. Testing for MSI status is recommended.

Research perspectives
First-line chemotherapy should be discussed with patients with CR-MAHA and gastric cancer, but the limited prognosis should be addressed by the attending oncologists. We do not encourage for second-line approaches. MSI-H tumors seem to act differently, even in fatal conditions such as CR-MAHA. It remains unclear, if combined chemo-immunotherapy in those patients would be beneficial.
REFERENCES


